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Inhibition of 5α-reductases impairs androgen and glucocorticoid metabolism and induces insulin 
resistance in humans and rodents. The contribution of hepatic glucocorticoids to these adverse 
metabolic changes was assessed utilizing a liver-selective glucocorticoid receptor (GR) 
antagonist, A-348441.  
Mice lacking 5α-reductase 1 (5αR1-KO) and their littermate controls were studied on a high fat 
diet, with or without A-348441(120 mg.kg-1.day-1). Male mice C57BL/6 (12 weeks) were also 
studied receiving dutasteride (1.8 mg.kg-1.day-1or vehicle) within a high fat diet, with or without 
A-348441.  
In 5αR1-KO mice, hepatic GR antagonism improved diet-induced insulin resistance, but not 
more than controls. Liver steatosis was not affected by hepatic GR antagonism in either 5αR1-
KO mice nor their littermate controls. In a second model of 5α-reductase inhibition using 
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dutasteride, hepatic GR antagonism with A-348441 attenuated excess weight gain brought about 
by dutasteride administration (7.03±0.5vs.2.13±0.4g; dutasteride vs. dutasteride+A-348441; 
mean±SEM, p<0.05) and normalized the associated hyperinsulinemia after glucose challenge 
(AUC: 235.9±17vs.329.3±16vs.198.4±25*ng.mL-1min-1; high fat, high fat+dutasteride, high 
fat+dutasteride+A-348441, respectively; *p<0.05). However, A-348441 again did not reverse 
dutasteride-induced liver steatosis.  
Thus, overall hepatic GR antagonism improves insulin resistance but not steatosis induced by 
high fat diet. Moreover, it attenuates excessive insulin resistance caused by pharmacological 
inhibition of 5α-reductases, but not genetic disruption of 5αR1. Dutasteride might put patients at 
increased risk of type 2 diabetes mellitus and reduced exposure to glucocorticoids may be 
beneficial.             
INTRODUCTION 
The consequences of glucocorticoid excess are well established, with links to metabolic disease 
exemplified by patients with Cushing’s syndrome. Glucocorticoids primarily mediate their 
actions through the glucocorticoid receptor (GR), activation of which can be regulated by pre-
receptor metabolism within tissues. For example, the 11β-hydroxysteroid dehydrogenases types 
1 and 2 have been shown to modulate GR and mineralocorticoid receptor activation respectively 
(1,2). The potential role of other enzymes such as the 5α-reductases (5αR), which are 
responsible for the rate-limiting step in glucocorticoid metabolism in modifying GR activation, is 
less clearly established.   
There are two main isozymes of 5α-reductases which can metabolize many pregnene 
steroids: type 2 (5αR2) is highly expressed in the male reproductive tract where it amplifies 
androgen action, whereas type 1 (5αR1) is most highly expressed in the liver, but also in adipose 
tissue and skeletal muscle at lower levels (3,4). 5α-Reductase inhibitors such as finasteride 
(which inhibits type 2) and dutasteride (which inhibits both isozymes) are prescribed for many 
men with prostate disease (5). A recent population based cohort study found the risk of 
developing new onset type 2 diabetes was higher in men exposed to 5α-reductase inhibitors 
compared with those receiving tamsulosin (6). Furthermore, human studies showed combined 
inhibition of 5αR1 and 5αR2 (but not 5αR2 alone) impaired insulin sensitivity and resulted in 
increased hepatic fat content compared to before dutasteride treatment (7,8). Similarly, genetic 
disruption of 5αR1, but not 5αR2, in mice (5αR1-KO) also caused hyperinsulinemia, weight 
gain, increased hepatic triglyceride deposition and a predisposition to irreversible liver disease 
(4,9). 
Given the abundance of 5αR1 in the liver and the characterized hepatic phenotype in 5αR1-
KO mice and humans receiving 5αR inhibitors, it is likely that the liver is a crucial site of steroid 
accumulation following 5αR1 inhibition or deficiency. While accumulation of either androgens 
or glucocorticoids could be responsible for adverse metabolic effects, androgen accumulation 
appears a less likely mechanism; non-selective inhibition of 5α-reductases in obese Zucker rats 
induced fatty liver in both castrated and intact rats (4) and female 5αR1-KO mice are more 
susceptible to hyperinsulinemia than males (10). Therefore, we hypothesized that hepatic 
glucocorticoid excess underpins the adverse metabolic changes observed following 5αR1 
inhibition or disruption, driving hepatic steatosis and insulin resistance. 
Systemic GR antagonism with compounds such as mifepristone (RU486) improves insulin 
and glucose homeostasis in ob/ob mice (11), but the site of action is uncertain and likely 
multiple, with effects confounded by compensatory hyper-corticosteronemia. To test our 
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hypothesis that the metabolic phenotype in mice with disruption of 5αR1 is driven by excess 
glucocorticoid action in the liver we employed the liver-selective GR antagonist, A-348441.  A-
348441 is a cholic acid conjugate of the GR antagonist RU486 (12) that selectively acts in the 
liver to antagonize the GR. In leptin deficient ob/ob mice, A-348441 successfully improved 
glucose homeostasis, without elevated circulating corticosterone (13). Using euglycemic-
hyperinsulinemic clamps, it was demonstrated to decrease hepatic glucose output and increased 
insulin sensitivity in fa/fa rats, a genetic model of obesity (13,14), making it a suitable model for 
our study. 
Research Methods and Design 
Chemicals were from Sigma (Poole, UK) and primers from Invitrogen Life Technologies 
(Paisley, UK), unless otherwise stated. All molecular biology reagents and kits were from 
Qiagen. Dutasteride was from AK Scientific (CA, USA) and A-348441 was a kind gift from 
KaroBio (Huddinge, Sweden). Diets were from Research Diets Inc. (New Jersey, USA), who 
also prepared custom high fat diets containing dutasteride and A-348441. 
Animals 
Male mice deficient in 5αR1 (5αR1-KO; n=8-11/group (housed as 2-4 mice/cage at 21°C), were 
bred in house by mating heterozygous mice on a mixed C57Bl6/SvEv/129 background (3,4) with 
corresponding mixed-strain wild-type littermates used as controls. C57BL6/J male mice were 
from Harlan (Bicester, UK). Animals were studied under UK Home Office license and had free 
access to drinking water and food. Animals were culled (0800-1030 h) by decapitation with 
trunk blood collected.  
Insulin signaling analysis 
Insulin signaling pathways were studied in a subset of C57BL/6 mice. These were fasted for 4 h 
(1000-1400 h) in clean cages and human insulin (0.75 U/kg body weight in saline) was given via 
intraperitoneal injection. These animals were culled via decapitation after 15 minutes. In all 
cases, tissues were dissected, wet weighed and snap frozen on dry ice or fixed in 10% formalin.  
GR antagonism in 5αR1-KO mice 
Male 5αR1-KO and corresponding littermate control mice (n = 8-11 per group; age 12 weeks) 
were randomly allocated to either: chow diet (11% fat, 0% sucrose, D12328); Western style high 
fat, high sucrose diet (HFD; 58% kcal fat, 13% kcal sucrose, D12331) alone; HFD containing A-
348441 (120 mg.kg-1.day-1). After 9 weeks of experimental diet, mice were fasted for 6 h (0800-
1400 h) before undergoing a glucose tolerance test (GTT, intraperitoneal injection, 2 mg.g-1), 
with blood taken by tail venesection at 0, 15, 30, 60 and 90 min. One week later, blood was taken 
at 0800 h for basal corticosterone measurement and two days later (after 10 weeks of 
experimental diet) mice were culled as above. A-348441 was mixed within the high fat diet to 
achieve long term administration without causing chronic stress that would result from repeat 
injections/gavages. This is particularly desirable since disruption of 5αR1-mediated 
corticosterone clearance impairs the corticosterone stress response (15).  
GR antagonism following pharmacological inhibition of 5αRs with dutasteride in C57BL/6 mice  
C57BL6/J male mice (n = 8-12 per group; age 12 weeks) were randomly allocated to either: 
chow diet; HFD alone; HFD containing A-348441 (120 mg.kg-1.day-1), HFD plus dutasteride 
(1.8 mg.kg-1.day-1), or HFD plus dutasteride plus A-348441 (same doses) for 4 weeks. GTTs (as 
above) were performed after 3 weeks of experimental diet. Mice were culled one week later 
(after 4 weeks of experimental diet). 
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Laboratory Analyses 
Biochemistry 
Plasma hormones were measured by ELISA as follows: corticosterone (Enzo Life Sciences, 
Exeter, UK; RRID: AB_2307314) and insulin (Crystal Chem, IL, USA; RRID: 2783626). 
Glucose by hexokinase assay (ThermoFisher, Loughborough, UK) and triglycerides 
(ThermoFisher, Hemel Hempstead, UK) and nonesterified fatty acids (NEFAs) (Zen-Bio, NC, 
USA) spectrophotometrically. Liver triglycerides were quantified as reported previously (16). 
Quantification of mRNAs by Real-Time Quantitative PCR 
RNA was extracted as previously described (4). mRNA transcript abundances were quantified by 
real-time PCR as previously described and with primers and probes as detailed in (4,17,18). 
Transcript abundances for genes of interest were normalized for the mean abundance of the 
reference genes, Tbp, Hprt and Actβ, the expression of which did not differ between groups. 
Western Blot Analysis 
Snap-frozen liver (~40 µg) was homogenized with a rotor blade in ice-cold RIPA buffer (Santa 
Cruz, Dallas, USA). Western blots were performed as previously described (17). Specific 
primary antibodies used were: monoclonal rabbit anti-IR β (RRID: AB_2280448, 19), polyclonal 
rabbit anti-phospho-AKT (Ser473) (RRID: AB_329825, 20), polyclonal rabbit anti- AKT 
(RRID:AB_ 329827, 21), polyclonal rabbit anti- phospho-GSK-3β (Ser9) (RRID:AB_331405, 
22), monoclonal rabbit anti-GSK-3β (RRID: AB_490890, 23) from Cell Signalling Technologies 
(Leiden, Netherlands); polyclonal anti-rabbit GR (RRID:AB_2155784, 24)  from Santa Cruz 
Biotechnology, Inc. (Heidelberg, Germany); monoclonal mouse anti-β-tubulin 
(RRID:AB_94650, 25), monoclonal mouse anti-IRS1 (RRID: AB_11214300, 26), monoclonal 
mouse anti-IRS2 (RRID:AB_10615782, 27) from Millipore Ltd (Watford, UK). Secondary 
antibodies were: IRDye 680RD goat anti-rabbit IgG (H+L) (RRID:AB_10956166, 28), IRDye 
800CW goat anti-rabbit IgG (H+L) (RRID:AB_621843, 29) and IRDye 800CW goat anti-mouse 
IgG (RRID:AB_2782997, 30) from LI-COR Biosciences Ltd (Cambridge, UK). Phospho 
antibodies were diluted 1:500 in bovine serum albumin (BSA; Cohn Fraction V, 5 % w/v in 
TBST), while all total protein primary antibodies were diluted 1:1000 in BSA (5 % w/v in 
TBST). Secondary antibodies were diluted 1:10000 in BSA when looking at phosphorylation of 
proteins, or milk when looking at total protein. Band intensities were quantified using the 
Odyssey Imaging System (LI-COR Biosciences, Cambridgeshire, UK). Quantification of 
proteins of interest was calculated by dividing their integrated intensity by that of the loading 
control (β-tubulin). Phospho-proteins were normalized to their corresponding bands of β-tubulin 
and a ratio of (phospho-protein/β-tubulin)/(total protein/β-tubulin) was used in final analysis.  
Statistical Analysis   
Data are mean±SEM, analysed with GraphPad Prism 6 (San Diego, CA), using Student’s t-test 
or 2-way ANOVA, with Sidak Post-hoc test as appropriate. Statistical significance was taken at 
p<0.05. 
Results 
Hepatic GR antagonism in mice with genetic disruption of 5αR1 
10 weeks of high fat diet was sufficient to induce an adverse metabolic phenotype in the wild-
type mice of mixed strain (“wild-type-HFD”) background, causing excess weight gain of ~4 g 
compared to chow diet (9.0±1.1 vs 4.8±0.5 g; p<0.05). Furthermore, fasting insulin was 
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
o
lo
g
y
D
ow
nloaded from
 https://academ
ic.oup.com
/endo/advance-article-abstract/doi/10.1210/en.2019-00236/5518336 by Edinburgh U
niversity user on 23 August 2019
AD
VA
NC
E 
AR
TI
CL
E
Endocrinology; Copyright 2019  DOI: 10.1210/en.2019-00236 
 
 
5
increased by high fat diet (2.8±0.4 vs 2.0±0.3 ng/mL, p<0.05) without raising fasting glucose 
(156.7±3.7 vs 151.6±9.9 mg/dL; HFD vs chow diet). Liver triglyceride levels were also 
increased by high fat diet (152.3±18.4 vs 36.97±9.4 µmol/g). The effects of A-348441 to 
attenuate the metabolic changes induced by 10 weeks of high fat diet were thus studied in 5αR1-
KO (“5αR1-KO-HFD”) and wildtype-HFD mice (the drug was not administered to animals 
receiving chow diet). Consistent with a lack of central effects and previous literature (12-14), 
basal circulating corticosterone was not altered in either genotype following administration of A-
348441 (Table 1).  
Weight gain induced by the high fat diet was attenuated by A-348441 in wild-type-HFD 
mice, but not in 5αR1-KO-HFD mice (Figure 1A, 1B, 1C). However, mass of specific adipose 
depots was not decreased by the drug of different by genotype (Table 1). A-348441 lowered 
fasting glucose in the wild-type-HFD mice only (Figure 1D, 1E, 1J), but had no effect on the 
overall glucose response to a GTT (Figure 1F). There was an overall effect of A-348441 to lower 
fasting insulin (Figure 1G, 1H, 1K) and insulin response to a GTT (Figure 1I) in mice of both 
genotypes. Similar to previously described (4), 5αR1-KO-HFD mice were predisposed to 
develop insulin resistance - with a trend to higher fasting insulin (Figure 1K) and increased 
insulin response to a glucose challenge compared to wild-type-HFD mice irrespective of the 
presence of A-348331 (Figure 1I). Surprisingly, 5αR1-KO-HFD mice overall had lower fasting 
NEFAs than the wild-type-HFD mice (Table 1). As a measure of adipose insulin sensitivity, 
NEFA suppression over the first 15 minutes of the GTT was measured. However, A-348441 did 
not influence NEFA suppression, but increased fasting NEFAs in the wild-type-HFD mice only 
(Table 1). Furthermore, as anticipated, 5αR1-KO-HFD mice overall had higher hepatic 
triglyceride levels than their wild-type controls but A-348441 did not lower hepatic or plasma 
triglyceride levels in either genotype (Figure 1L, Table 1).  
Liver selective GR antagonism following dutasteride administration in C57BL/6 mice 
Mice on a C57BL/6 background are predisposed to diet-induced obesity and were studied over a 
shorter time-frame. After only 4 weeks, high fat diet induced weight gain in excess of that in 
chow fed animals (6.3±0.4 vs 4.0.±0.1 g; p<0.05), accompanied by a doubling in fasting insulin 
of 2.1±0.2 vs 0.8 ±0.1 ng/mL (p<0.05) as well as an increase in hepatic triglyceride content 
(22.3±1.3 µmol/g vs 10.5±1.7 p<0.05). Similar to the littermate controls of the 5αR1-KO mice 
(Figure 1), C57BL/6 mice on A-348441 had reduced weight gain (Figure 2A), no changes in 
glucose tolerance (Figure 2D), but lowered insulin levels (Figure 2G).  
Successful administration of dutasteride was confirmed by a reduction in prostate size (Table 
2). Co-administration of dutasteride in the high fat diet exacerbated the adverse metabolic 
phenotype in C57BL/6. Body weight gain increased after 4 weeks compared to high fat diet 
alone (Figure 2C), with increased adipose weight in the omental depot only (Table 2). 
Dutasteride increased insulin response to a bolus of glucose during a GTT compared to high fat 
diet alone (Figure 2I), as well as fasting insulin (Figure 2K), without altering the glucose 
response to GTT or fasting glucose (Figure 2F, 2J).  Compared with mice receiving high fat diet 
alone, mice fed dutasteride had increased hepatic triglyceride levels (Figure 2L) without 
differences in plasma triglyceride, fasting plasma NEFA or suppression of NEFAs following 
glucose challenge (Table 2). Food intake was not measured per animal, but on a cage basis (with 
limited power of n=3), appeared less in animals fed A-348441, irrespective of 5α-R status 
(16.9±0.8 vs 13.5±0.7 kCal/mouse/day) 
In contrast with genetic deletion of 5αR1, co-administration of A-348441 with dutasteride 
reduced the excess weight gain (Figure 2B), in parallel with reduced expansion of visceral 
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adipose depots and lower fasting NEFAs (Table 2). Co-administration of A-348441 normalized 
the raised fasting insulin and insulin response to GTT caused by dutasteride (Figure 2I, 2K), 
again without affecting fasting glucose or glucose response during a GTT (Figure 2E, 2H). As in 
the 5αR1-KO mice, co-administration of A-348441 did not abrogate the raised liver triglyceride 
levels brought about by dutasteride (Figure 2L), nor alter NEFA suppression (Table 2).  
Effects of A-348441 on glucocorticoid and bile-acid sensitive hepatic pathways following 
administration to C57BL/6 mice 
As expected, dutasteride treatment increased the expression of glucocorticoid-sensitive genes 
such as Per1 in the liver (Figure 3A). Interestingly, it also resulted in reduced expression of Sgk 
transcript, whereas Gilz was unaffected. Liver-selective GR antagonism did not alter expression 
of any of these glucocorticoid-sensitive transcripts (Figure 3A). Neither dutasteride nor A-
348441 affected hepatic abundance of Nr3c1 mRNA (Figure 3A). 
Transcript abundance of genes involved in bile acid signaling was also investigated. A-
348441 lowered Cyp7a1 mRNA abundance and increased Shp abundance compared to high fat 
diet (Figure 3C). Dutasteride alone also lowered Cyp7a1 mRNA abundance but not Shp. A-
348441 administered in combination with dutasteride had no further effect on Cyp7a1 transcript 
abundance compared to dutasteride administration alone.  
Hepatic insulin signaling is unaffected by A-348441 administration   
A-348441 did not alter total protein levels of IR, IRS2, AKT or GSK-3β in the liver (Figure 4A-
C). A-348441 lowered Gys2 transcript levels only in the presence of dutasteride. Although 
dutasteride decreased Fas mRNA levels, it had little effect on other hepatic metabolic transcripts 
(Figure 3B). A-348441 treatment increased transcript abundance of Insr, Irs1, Ppargc1a, Fatp2, 
with a trend (p=0.07) for higher Irs2 mRNA transcripts (Figure 3B). When administered in 
combination with dutasteride, A-348441 lowered transcript abundance of Gys2 only. 
To better assess insulin signaling, we gave a subset of mice in each of the treatment groups a 
bolus of insulin following a 4 hour fast and collected tissue 15 minutes later. However, no 
changes were observed in pSer473AKT and pSer9 GSK-3β signal in liver (Figure 4D, 4E). 
Discussion 
Deficiency or inhibition of 5αR1 predisposes men and mice to insulin resistance and fatty liver 
(4,7-9). However, since 5αR1 can metabolize multiple steroids, notably both glucocorticoids and 
androgens, it has been unclear which hormone plays the more crucial role in the phenotype. 
Rodents with deficiency in 5αR1 develop hyperinsulinemia and hepatic steatosis even after 
androgen levels were decreased through castration (4), implicating glucocorticoids as the key 
hormone involved. Since 5αR1 is highly expressed in the liver, an organ crucial to metabolic 
balance, and glucocorticoid levels in this tissue are approximately doubled in 5αR1-KO (4), we 
therefore hypothesized that the predisposition to insulin resistance and fatty liver following 5αR1 
deficiency was due to an increase in glucocorticoid action in the liver. Using A-348441, a liver-
selective hepatic GR antagonist, we demonstrated in two models of 5αR1 deficiency, 5αR1-KO 
mice and administration of dutasteride (a dual 5α-reductase inhibitor), that glucocorticoids 
contribute to the phenotype. 
To test this hypothesis, we initially used a genetic approach, utilizing 5αR1-KO mice. These 
are bred on a mixed genetic background (3) and differences in metabolic parameters between 
5αR1-KO mice and their littermate controls develop slowly on high-fat diet (4,9). The 
intervention with A-348441 was commenced at 12 weeks of age for 10 weeks during the decline 
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in metabolic health. At this time point, 5αR1-KO mice on a high fat diet had increased insulin 
levels and greater insulin response during GTT compared with their littermate controls, but as 
expected, differences in weight were not yet observed (this aspect of the phenotype takes 6 
months to manifest (4,9)). Interestingly, the predisposition to fatty liver in 5αR1-KO mice 
compared to their littermate controls was also already evident over this shorter timeframe and 
before overt changes in body weight between the genotypes was observed.  
The outcome of treatment with A-348441 in the wild-type mice was similar to that observed 
in the fa/fa rats (13,14), with improved insulin sensitivity and attenuation of weight gain. 
Surprisingly, hepatic steatosis was unresponsive to hepatic GR antagonism. Previously genetic 
disruption of hepatic GR on a db/db background had attenuated hepatic triglyceride 
accumulation (31) and likewise, amplification of hepatic generation of glucocorticoids by over-
expression of 11β-hydroxysteroid dehydrogenase 1 exacerbated steatosis (32). However, the lack 
of change seen here is in agreement with previous work from Macfarlane et al. (2014) where 
systemic glucocorticoid blockade with RU486 did not ameliorate excess liver fat in patients with 
type 2 diabetes mellitus (33). The beneficial metabolic changes brought about by A-348441 were 
less marked in 5αR1-KO mice compared with littermate controls. Whereas administration of A-
348441 attenuated the excess weight gain induced by high fat diet in the littermate control mice, 
this was unaffected in 5αR1-KO mice. In terms of glucose disposal, A-348441 reversed the 
hyperinsulinemia to a similar extent between the 5αR1-KO mice and their littermate controls. 
Again, hepatic steatosis caused by the high fat diet was unresponsive to intervention and the 
5αR1-KO maintained higher liver fat than their littermate controls on both diets. This is 
supported by the fact that A-348441 did not lower transcript abundance of Fatp2 nor Fatp5 in 
the liver. 
Given the overall phenotype of the 5αR1-KO improved but remained different from wild-
type, these observations suggest that GR activation plays a role in high fat diet-induced 
metabolic dysfunction on this mixed genetic background, but do not support the hypothesis that 
the it is solely glucocorticoid mediated, unless insufficient drug had been administered, which 
we believe unlikely. Had excess GR activation been singly responsible, the difference between 
genotypes would have been negated. Equivalent doses of RU486 to the dose of A-348441 used 
here and common in mouse models would be expected to achieve concentrations in the blood 
well in excess of those of corticosterone (~100 nM) and hence unlikely to be limiting in the liver 
(34,35).  
To gain further insight, hepatic-selective GR antagonism was pursued in a second model, that 
of pharmacological inhibition with dutasteride, to better reflect the clinical therapeutic scenario. 
The 5αR1-KO mice have life-long deficiency in steroid metabolism, including during 
development, and may have undergone compensatory changes in steroid hormone action and 
metabolism. In a clinical setting, 5αR inhibition generally starts later in middle-aged adults. 
Dutasteride, a dual 5αR inhibitor, was administered to C57BL/6 mice, a strain which is 
predisposed to become obese, hyperglycemic and hyperinsulinemic due to a naturally occurring 
deletion in nicotinamide nucleotide transhydrogenase (36). Indeed, C57BL/6 mice were glucose 
intolerant and hyperinsulinemic after only 3 weeks of high fat diet, and thus this shorter time-
frame of study was chosen, matching the insulin increment in wild-type mice in the previous 
experiment. The ability of 5αR inhibition to adversely affect metabolism was apparent after 4 
weeks of treatment, reminiscent of studies in humans (4,7). Specifically, dutasteride exacerbated 
weight gain, increased fasting insulin and insulin response to a GTT and induced hepatic 
steatosis in mice fed high fat diet (4). 
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As with the wild-type controls of 5αR1-KO mice, high fat diet-fed C57BL/6 mice treated 
with A-348441 alone demonstrated an improved metabolic phenotype. Importantly, the 
exacerbation of metabolic dysfunction by dutasteride was also prevented by A-348441, 
highlighting a substantial role of hepatic glucocorticoids; weight gain was normalized to that of 
chow fed mice and insulin response to a glucose challenge and plasma triglycerides levels all 
decreased. Moreover, white adipose depots were reduced in weight. Systemic benefits may have 
been caused through hemocrine effects of hepatic metabolic mediators, as opposed to direct 
effects of the liver-selective drug. Indeed, other studies have demonstrated manipulation of 
metabolic signals in the liver such as FOXO1 and IR, as well as PI3K activity, can indirectly 
affect adipose tissue mass and systemic insulin sensitivity (37). Notably, however, hepatic 
steatosis was again not affected by hepatic GR antagonism, reinforcing the suggestion of a 
different etiology. Previous studies showed excess steatosis induced by pharmacological 
inhibition of 5αRs was also not reversed by castration, which suggests androgens alone are also 
not the sole cause (4). Either a complex interplay between glucocorticoids and androgens 
underpins the liver steatosis (38) or alternative hormonal pathways are involved. Nevertheless, 
we found most aspects of the observed adverse metabolic phenotype were responsive to GR 
blockade suggesting that excess hepatic glucocorticoid action plays a significant role in 
mediating many of the metabolic effects of dutasteride. To further confirm the contribution of 
increased hepatic glucocorticoid levels to changes in insulin sensitivity and hepatic steatosis, 
dutasteride could be administrated to liver-specific GR knockout mice on high fat diet. 
To gain insight into the potential mechanism responding to hepatic GR antagonism, hepatic 
transcript abundance of genes involved in insulin signaling and the lipid metabolism were 
studied. The level of Nr3c1 (GR) mRNA was unaffected by the drug. Per1 mRNA was studied 
as a known GR-responsive transcript. The levels of Per 1 were elevated by dutasteride, but did 
not suppress following GR antagonism. Indeed, very few changes in hepatic transcripts that 
might explain the phenotypic changes were seen in response to GR antagonism, with only some 
limited increase in genes associated with insulin signaling such as Insr, Irs1 and Ppargc1a and a 
small reduction in Gys2. However, a similar lack of regulation of genes involved in 
gluconeogenesis or lipid metabolism was observed when hepatic glucocorticoid ligand 
availability was suppressed in mice with liver-selective disruption of 11β-hydroxysteroid 
dehydrogenase 1 (39). Protein expression from the insulin signaling pathway was also explored 
under insulin stimulation but A-348441 had no effect on the total or phosphorylated state of 
these proteins in the liver (40,41). Further studies using insulin clamps would permit greater 
insight and a greater difference might be observed if the tissues were collected after a longer 
duration of high fat diet and A-348441. 
Given haemocrine mechanisms may underpin the improved phenotype, it is important to 
consider the tissue-selectivity of the antagonist. The drug had been developed to attenuate 
hepatic GR stimulation; pre-dosing with A-348441 antagonized glucocorticoid-induced up-
regulation of hepatic TAT activity by 79% and suppressed glucocorticoid-induced hepatic 
glycogen formation by 59% (13). Furthermore, compared to RU486, a systemic GR antagonist, 
A-348441 had substantially less effects in non-hepatic tissues e.g. was 12-fold less potent in 
preventing glucocorticoid–induced up-regulation of glutamine synthetase in L6 skeletal muscle 
myocytes and 15-fold less potent in a glucocorticoid-stimulated model of adipocyte 
differentiation in 3T3-L1 cells (13). This highly liver-selective profile avoided adverse effects on 
HPA axis incurred through systemic actions or central GR antagonism. In line with previous 
studies, we were able to recapitulate that A-348441 did not affect circulating concentrations of 
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corticosterone suggesting that negative feedback vis GR within the brain was unaffected by the 
presence of an antagonist, suggesting minimal circulating levels (13).   
GR is the most likely target for the drug, but being a conjugate of RU486 and cholic acid, A-
348441 is hepato-selective through the presence of a bile acid. Bile acids can modulate insulin 
signaling pathways via nuclear hormone receptors such as farnesoid x receptor-α (FXRα) as well 
as GR (42,43). It was thought unlikely that A-348441 would have off target effects on the bile 
acid pathway as the Kd for binding of cholic acid to FXRα is exceedingly high - 36 mM versus a 
Ki of 0.27 nM for A-348441 to GR (12) and not anticipated with the given doses. However, we 
found that A-348441 lowered Cyp7a1 and increased Shp mRNA abundance. Nonetheless,  it is 
likely that the effects of GR and FXRα are linked - hepatic GR can regulate systemic bile acid 
homeostasis, with glucocorticoids inhibiting the transcriptional activity of FXR (43,44). 
Furthermore, SHP is a corepressor of the glucocorticoid receptor (45); increased mRNA of Shp 
would still have the end result of decreased GR action. Interestingly, Cyp7a1 and Shp mRNA 
abundance in mice fed dutasteride were not significantly different from the mice given 
dutasteride along with A-348441. Altogether, A-348441 may influence hepatic bile acid 
signaling, but the effects of A-348441 in ameliorating the adverse phenotype caused by 
dutasteride were not through the same pathways. Had A-348441 lowered androgen levels and 
activation of the androgen receptor, this would confound our interpretation, but we see no 
evidence of this e.g. lack of reduction in prostate weight.  
In summary, most but not all of the adverse metabolic effects of diet-induced obesity brought 
about by inhibition of 5αR1 with dutasteride can be reversed by liver-selective GR antagonism. 
Our data support a substantial role for increased hepatic GR activation in the adverse metabolic 
phenotype observed following pharmacological inhibition and a contributory role after genetic 
disruption of 5αR1, however the signaling pathways underpinning the changes were elusive. A-
348441 proved a useful tool to dissect the role of liver GR in regulating metabolism and has 
revealed that many of the consequences of high fat diet in animal models, with the crucial 
exception of steatosis, can be reversed by targeting hepatic GR. The study consolidates the 
hypothesis that men receiving dual 5αR inhibitors are exposed to challenges to their metabolic 
health. Concomitant administration of  therapies which attenuate glucocorticoid action, such as 
11β-hydroxysteroid dehydrogenase 1 inhibitors (46,47) may prove to be of benefit.  
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Figure 1: Body weight gain and glucose homeostasis in 5α-reductase 1 deficient (knockout) 
mice and their wild-type controls following a high fat diet and administration of A-348441 
for 10 weeks. Mice were fed high fat or high fat+A-348441 diet. A-348441 ameliorated the 
increase in body weight gain in the wild-type (A) but not knockout (B, C) mice. A-348441 did 
not significantly affect glucose levels in either genotype (D, E, F) in response to glucose 
tolerance tests, but had an overall effect to ameliorate the increase in insulin levels (G, H, I) 
(p=0.004). After 9 weeks of experimental diet, A-348441 lowered fasting glucose in the wild-
type mice only (J), but ameliorated the increase in fasting insulin in both genotypes (K). 
Knockout mice overall had higher insulin (I) and hepatic triglyceride levels (L) than wild-type 
mice. Data are mean±SEM and presented by individual genotype for clarity, with analysis of all 
data by two-way ANOVA followed by Sidak post-hoc test ($p<0.05 vs matched genotype 
receiving high fat diet), n=8-11/group. NS = not significant, n=8-11/group. For overall ANOVA, 
* p<0.05, ** p<0.01, *** p< 0.001. 
Figure 2: Body weight and glucose homeostasis in C57BL/6 mice following dutasteride and 
A-348441 administration for 4 weeks. C57BL/6 mice were fed high fat, high fat+A-348441, 
high fat + dutasteride or high fat + dutasteride + A-348441 diet. A-348441 ameliorated increased 
body weight in both mice fed high fat diet alone (A) or high fat + dutasteride diet (B). Mice on 
high fat diet + dutasteride had increased body weight gain versus high fat diet alone (C). Glucose 
tolerance was not changed by dutasteride or A-348441 administration (D, E, F). A-348441 
lowered raised insulin levels during a GTT induced by both high fat diet alone (G) or in 
combination with dutasteride (H).  Dutasteride increased insulin levels compared to mice on a 
high fat diet alone (I). A-348441 had no effect on fasting glucose (J) but normalized the 
increased fasting insulin caused by dutasteride upon high fat diet (K). With a high fat diet, there 
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was an overall effect for dutasteride to increase hepatic triglyceride levels (L), but A-348441 did 
not ameliorate this rise. Data are mean±SEM and presented by 5α-reductase status for clarity, 
with analysis of all data by two-way ANOVA at each time point followed by Sidak post-hoc test 
($p<0.05 vs. high fat diet; #p<0.05 vs. high fat+dutasteride), n=8-12/group. NS = not significant, 
n=8-12/group. For overall ANOVA, * p<0.05, ** p<0.01, *** p< 0.001. 
Figure 3: Response of hepatic transcripts to A-348441 in C57BL/6 mice after 4 weeks of 
experimental diet. mRNA abundances were quantified for Nr3c1, Per1, Gilz, Sgk, Insr, Irs1, 
Irs2, Ppara, Pparg, Ppargc1a, Srebf1, Pepck, Gys2, Fatp2, Fatp5, Angpt12, Fas, Cyp7a1 and 
Shp. Amongst glucocorticoid sensitive genes, dutasteride increased Per1 and lowered Sgk (A), 
while A-348441 had no effect. Dutasteride also lowered Fas mRNA, while A-348441 increased 
transcript abundance for Insr, Irs1 and Ppargc1a. When administered in combination with 
dutasteride, A-348441 lowered Gys2 transcript levels (B). Both dutasteride and A-348441 
lowered Cyp7a1 abundance but only A-348441 alone increased Shp transcript levels compared to 
high fat diet (C). Data are mean±SEM and analyzed by two-way ANOVA followed by Sidak 
post-hoc test ($p<0.05 vs. high fat diet; #p<0.05 vs. high fat+dutasteride). For overall ANOVA, 
* p<0.05 effect of dutasteride, n=8-12/group, n=10-11/group.  
Figure 4: Response of hepatic insulin signaling proteins to A-348441 in C57BL/6 mice.  
Total protein levels of hepatic IR (A), IRS2 (A), AKT (B) and GSK-3β (C) did not change in 
response to administration of A-348441. Phosphorylation status of hepatic pSer473AKT (D) and 
hepatic pSer9GSK-3β (E) following insulin stimulation did not change in response to the addition 
of A-348441. Data are mean±SEM and analyzed by Student t-test - *p<0.05 vs. high fat diet, 
n=6 (high fat) -12 (high fat + A-348441)/group.  
Table 1 Indices of metabolism in wild-type and 5α-reductase 1 deficient (knockout) mice.  
Wild-type Wild-type Knockout Knockout 
Effect of 
A-348441 
Effect of 
genotype Interaction 
 HF diet 
HF + A-
348441 diet HF diet 
HF + A-
348441 diet P value P value P value 
Total weight gain (g) 8.99±1.11 5.04±0.62* 8.83±1.37 7.61±0.55 <0.01 0.21 0.16 
Tissues (% Body weight)        
Omental adipose 0.062±0.008 0.048±0.005 0.079±0.009 0.062±0.007 0.05 0.06 0.85 
Liver 4.52±0.16 4.38±0.12 4.55±0.12 4.83±0.08 0.59 0.07 0.12 
Gonadal adipose 3.91±0.32 3.33±0.21 4.14±0.36 3.83±0.13 0.11 0.19 0.61 
Perinephric adipose 1.30±0.11 1.11±0.08 1.42±0.11 1.38±0.08 0.24 0.06 0.47 
Mesenteric adipose 1.60±0.10 1.28±0.07 1.59±0.22 1.59±0.10 0.23 0.24 0.21 
Subcutaneous adipose 2.08±0.26 1.77±0.12 2.54±0.34 2.01±0.18 0.08 0.14 0.65 
Quadriceps muscle 1.14±0.06 1.19±0.03 1.05±0.05 1.23±0.02 0.20 0.10 0.76 
Interscapular adipose 0.51±0.03 0.54±0.05 0.52±0.03 0.53±0.06 0.36 0.05 0.64 
Biochemistry 
Corticosterone (nM) 35.2±2.2 37.9±2.1 35.9±3.5 38.5±3.3 0.10 0.45 0.82 
Plasma TGA (mmol/L) 2.07±0.20 1.79±0.16 2.01±0.20 1.87±0.07 0.14 0.80 0.92 
Fasting NEFA (mM) 1.58±0.12 1.91±0.14 1.26±0.08 1.38±0.10 0.06 <0.01 0.40 
∆NEFA (mM)  
0.29±0.16 0.44±0.10 0.06±0.11 0.38±0.07 0.04 0.15 0.33 (0-15min of GTT) 
Mice were fed high fat (HF) or HF+A-348441 diet for 10 weeks. Data are mean ± SEM, compared by two-way 
ANOVA with Sidak post hoc tests. Codes of comparisons (p<0.05) within same genotype, * vs HF diet: n=8-
11/group. TGA = triglycerides; NEFA = non-esterified fatty acids; GTT = glucose tolerance test. 
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 HF 
HF + A-
348441 
HF + 
Dutasteride 
HF + 
Dutasteride +A-
348841 
Effect of 
dutasteride 
Effect of 
A-348441 Interaction 
Total weight gain (g) 5.71±0.37 3.18±0.25* 7.03±0.52* 2.13±0.42† 0.73 <0.001 0.005 
Tissue weight (% Body 
weight)        
Omental adipose 0.049±0.003 0.036±0.003 0.069±0.006* 0.043±0.008† 0.010 <0.001 0.195 
Liver 4.89±0.08 4.71±0.12 5.16±0.12 4.56±0.28 0.704 0.016 0.187 
Gonadal adipose 3.28±0.17 2.32±0.19* 3.46±0.17 2.07±0.18 0.838 <0.001 0.249 
Perinephric adipose 0.99±0.05 0.56±0.06* 0.99±0.06 0.51±0.07 0.726 <0.001 0646 
Mesenteric adipose 1.46±0.09 0.97±0.07* 1.56±0.09 1.04±0.05 0.354 <0.001 0.844 
Subcutaneous adipose 1.53±0.09 1.02±0.06* 1.85±0.13 1.37±0.15† 0.004 <0.001 0.934 
Quadriceps muscle 1.24±0.03 1.24±0.04 1.17±0.03 1.29±0.03 0.734 0.098 0.092 
Interscapular adipose 0.38±0.03 0.42±0.03 0.44±0.03 0.32±0.02† 0.507 0.184 0.013 
Prostate 0.049±0.005 NC 0.024±0.004* 0.034±0.003* N/A N/A N/A 
Biochemistry 
Corticosterone (nM) 86.23±10.9 106.6±23.4 32.69±3.9*  88.34±22.8 0.035 0.027 0.29 
Plasma TGA (mmol/L) 2.03±0.14 1.56±0.13* 2.07±0.12 1.76±0.13 0.37 0.008 0.57 
Fasting NEFA (mM) 2.13±0.11 1.98±0.15 2.08±0.01 1.54±0.15† 0.15 0.048 0.25 
∆NEFA  (0-15min of 
GTT) 1.11±0.11 0.98±0.16 1.36±0.15 0.89±0.13 0.61 0.08 0.31 
Mice were fed high fat (HF), HF+A-348441, HF+dutasteride or HF+dutasteride+A-348441 diet for 4 weeks. Data 
are mean ± SEM, compared with two-way ANOVA with Sidak post hoc tests, *p<0.05 vs HF diet alone, †p<0.05 vs 
HF + dutasteride. Prostate weight was compared by one-way ANOVA, p=0.002. n=8-12/group. NC is not collected; 
N/A is not applicable; TGA = triglycerides; NEFA = non-esterified fatty acids; GTT = glucose tolerance test.  
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
o
lo
g
y
Table 2 Indices of metabolism in C57BL/6 mice fed high fat (HF) diet, with or without A-
348441 and/or without dutasteride.  D
ow
nloaded from
 https://academ
ic.oup.com
/endo/advance-article-abstract/doi/10.1210/en.2019-00236/5518336 by Edinburgh U
niversity user on 23 August 2019
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
o
lo
g
y
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
o
lo
g
y
AD
VA
NC
E 
AR
TI
CL
E
Control Knockout
0
50
100
150
200
250
Liv
er
 tr
igl
yc
er
ide
 (u
m
ol/
g) High fat + A-348441
High fat
Control Knockout
0.0
0.2
0.4
0.6
0.8
1.0
Fa
st
in
g 
in
su
lin
 (n
m
ol
/L
) High fat
High fat + A-348441
0 15 30 60 90
0.0
0.5
1.0
1.5
Minutes
In
su
lin
 (n
m
ol
/L
)
High fat
High Fat + A-348441
1 2 3 4 5 6 7 8 9 10
0
5
10
15
Weeks
W
ei
gh
t g
ai
n 
(g
)
High fat
High fat + A-348441
$
$ $ $ $ $
$ $$
Wild-type-HFD 5⍺R1-KO-HFD
0 15 30 60 90
0
5
10
15
20
25
Minutes
G
lu
co
se
 (m
m
ol
/L
)
High fat
High fat + A-348441
$
$
$
A)
1 2 3 4 5 6 7 8 9 10
0
5
10
15
Weeks
W
ei
gh
t g
ai
n 
(g
)
High fat
High fat + A-348441
C)
E)
G)
B)
D)
$ Control Knockout0
5
10
15
W
ei
gh
t g
ai
n 
(g
)
Control Knockout
0.0
0.5
1.0
1.5
2.0
Gl
uc
os
e A
UC
 ((
m
m
ol/
L*
m
in)
*1
03
)
High fat
High fat + A-348441
Control Knockout
0
2
4
6
8
10
Fa
st
in
g 
gl
uc
os
e 
(m
m
ol
/L
)
Control Knockout
0
5
15
W
ei
gh
t g
ai
n 
(g
)
A-348441   **
Genotype   NS
Interaction  NS
$
Control Knockout
0.0
0.5
1.0
1.5
2.0
Gl
uc
os
e A
UC
 ((
m
m
ol/
L*
m
in)
*1
03
)
High fat
High fat + A-348441
Control Knockout
0.0
0.5
1.0
1.5
2.0
Gl
uc
os
e A
UC
 ((
m
m
ol/
L*
m
in)
*1
03
)
High fat
High fat + A-348441
A-348441    **
Genotype     *
Interaction  NSH) I)
A-348441   NS
Genotype     *
Interaction  NS
Control Knockout
0.0
0.5
1.0
1.5
2.0
Gl
uc
os
e A
UC
 ((
m
m
ol/
L*
m
in)
*1
03
)
High fat
High fat + A-348441
Control Knockout
0.0
0.5
1.0
1.5
2.0
Gl
uc
os
e A
UC
 ((
m
m
ol/
L*
m
in)
*1
03
)
High fat
High fat + A-348441
A-348441     ***
Genotype  p=0.08
Interaction    NS
A-348441     *
Genotype   NS
Interaction  NS
J) K) L)
0 15 30 60 90
0
5
10
15
20
25
Minutes
G
lu
co
se
 (m
m
ol
/L
)
High fat
High fat + A-348441
Control Knockout
0.0
0.5
1.0
1.5
2.0
Gl
uc
os
e A
UC
 ((
m
m
ol/
L*
m
in)
*1
03
)
High fat
High fat + A-348441
A-348441   NS
Genotype   NS
Interaction  NS
F)
$
0 15 30 60 90
0.0
0.5
1.0
1.5
Minutes
In
su
lin
 (n
m
ol
/L
)
High fat
High Fat + A-348441
0 15 30 60 90
0
5
10
15
20
2
Minutes
G
lu
co
se
 (m
m
ol
/L
)
High fat
High fat + A-348441
$
$ $
0 15 30 60 90
0
5
10
15
20
25
Minutes
G
lu
co
se
 (m
m
ol
/L
)
High fat
High fat + A-348441
Control Knockout
0
2
4
6
8
10
In
su
lin
 A
U
C
 ((
nm
ol
/L
*m
in
)*
10
2 )
High fat + A-348441
High fat
Control Knockout
0.0
0.5
1.0
1.5
2.0
Gl
uc
os
e A
UC
 ((
m
m
ol/
L*
m
in)
*1
03
)
High fat
High fat + A-348441
p=0.098
p=0.051
$
$
Control Knockout
0.0
0.5
1.0
1.5
2.0
Gl
uc
os
e A
UC
 ((
m
m
ol/
L*
m
in)
*1
03
)
High fat
High fat + A-348441
$
$
Wild-type   Knockout
Wild-type   Knockout
Wild-type   Knockout
Wild-type   Knockout Wild-type   Knockout Wild-type   Knockout
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
o
lo
g
y
D
ow
nloaded from
 https://academ
ic.oup.com
/endo/advance-article-abstract/doi/10.1210/en.2019-00236/5518336 by Edinburgh U
niversity user on 23 August 2019
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
o
lo
g
y
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
o
lo
g
y
AD
VA
NC
E 
AR
TI
CL
E
High fat High fat + dutasteride
0
10
20
30
40
Liv
er
 tr
igl
yc
er
ide
 (u
m
ol/
g)
High fat High fat + dutasteride
0.0
0.1
0.2
0.3
0.4
0.5
Fa
st
in
g 
in
su
lin
 (n
m
ol
/L
) -A-348441
+A-348441
Wild-type (C57BL/6) 5⍺R1 inhibition
A) C)
E)
G)
B)
D)
A-348441     ***
Dutasteride  NS
Interaction     **
A-348441      *
Dutasteride   *
Interaction  NSH) I)
J) K) L)
F)
1 2 3 4
0
2
4
6
8
Weeks
W
ei
gh
t g
ai
n 
(g
)
High fat
High fat + A-348441
$ $ $
$
1 2 3 4
0
2
4
6
8
Weeks
W
ei
gh
t g
ai
n 
(g
)
High fat + dutasteride
High fat + 
dutaster de + 
A-348441
# # #
#
1 2 3 4
0
2
4
6
8
Weeks
W
ei
gh
t g
ai
n 
(g
)
High fat
High fat + A-348441
1 2 3 4
0
2
4
6
8
Weeks
W
ei
gh
t g
ai
n 
(g
)
High fat + dutasteride
High fat + dutasteride 
+ A-348441
High fat High fat + dutasteride
0
2
4
6
8
W
ei
gh
t g
ai
n 
(g
)
-A-348441
+A-348441
High fat High fat + dutasteride
0
2
4
6
8
W
ei
gh
t g
ai
n 
(g
)
-A-348441
+A-348441
$
$
#
High fat High fat + dutasteride
0
2
4
6
8
W
ei
gh
t g
ai
n 
(g
)
-A-348441
+A-348441
High fat High fat + dutasteride
0.0
0.5
1.0
1.5
2.0
Gl
uc
os
e A
UC
 ((
m
m
ol/
L*
m
in)
*1
03
)
High fat High fat + dutasteride
0
5
10
15
Fa
st
in
g 
gl
uc
os
e 
(m
m
ol
/L
) -A-348441
+A-348441
$
$
#
A-348441    NS
Dutasteride   *
Interaction   NS
A-348441   ***
Dutasteride  *
Interaction  NS
A-348441    NS
Dutasteride NS
Interaction   NS
High fat High fat + dutasteride
0
2
4
6
8
W
ei
gh
t g
ai
n 
(g
)
-A-348 41
+A-348 41
1 2 3 4
0
2
4
6
8
Weeks
W
ei
gh
t g
ai
n 
(g
)
High fat
High fat + A-348441
1 2 3 4
0
2
4
6
8
Weeks
W
ei
gh
t g
ai
n 
(g
)
High fat + dutasteride
High fat + dutasteride 
+ A-348441
High fat High fat + dutasteride
0
2
4
6
8
W
ei
gh
t g
ai
n 
(g
)
-A-348441
+A-348441
High fat High fat + dutasteride
0
2
4
6
8
W
ei
gh
t g
ai
n 
(g
)
-A-348441
+A-348441
High fat High fat + dutasteride
0
2
4
6
8
W
ei
gh
t g
ai
n 
(g
)
-A-348441
+A-348441
0 15 30 60 90
0.0
0.2
0.4
0.6
0.8
Minutes
In
su
lin
 (n
m
ol
/L
)
High fat
High Fat + A-348441
$
$
0 15 30 60 90
0.0
0.2
0.4
0.6
0.8
1.0
Minutes
In
su
lin
 (n
m
ol
/L
)
#
#
# # #
High fat High fat + dutasteride
0
2
4
6
8
In
su
lin
 A
U
C
 ((
nm
ol
/L
*m
in
)*
10
2 )
$ #
$
0 15 30 60 90
0
10
20
30
Minutes
G
lu
co
se
 (m
m
ol
/L
)
$
1 2 3 4
0
2
4
6
8
Weeks
W
ei
gh
t g
ai
n 
(g
)
High fat
High fat + A-348441
A-348441   NS
Dutasteride NS
Interaction  NS
#
$
0 15 30 60 90
0
10
20
30
Minutes
G
lu
co
se
 (m
m
ol
/L
)
1 2 3 4
0
2
4
6
8
Weeks
W
ei
gh
t g
ai
n 
(g
)
High fat + dutasteride
High fat + dutasteride 
+ A-348441
High fat High fat + dutasteride
0
2
4
6
8
W
ei
gh
t g
ai
n 
(g
)
-A-348441
+A-348441
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
o
lo
g
y
D
ow
nloaded from
 https://academ
ic.oup.com
/endo/advance-article-abstract/doi/10.1210/en.2019-00236/5518336 by Edinburgh U
niversity user on 23 August 2019
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
o
lo
g
y
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
o
lo
g
y
AD
VA
NC
E 
AR
TI
CL
E
Nr
3c
1
Pe
r1 Gi
lz
Sg
k
0.0
0.5
1.0
1.5
2.0
m
R
N
A 
ab
un
da
nc
e 
(re
la
tiv
e 
to
 h
ou
se
ke
ep
in
g 
ge
ne
s)
High Fat
High Fat + A-348441
High Fat + Dutasteride
High Fat + Dutasteride + A-348441
Ins
r
Irs
1
Irs
2
Pp
ara
Pp
arg
Pp
arg
c1
a
Sr
eb
f1
Pe
pc
k
Gy
s2
Fa
tp2
Fa
tp5
An
gp
tl2 Fa
s
0.0
0.5
1.0
1.5
2.0
m
R
N
A 
ab
un
da
nc
e 
(re
la
tiv
e 
to
 h
ou
se
ke
ep
in
g 
ge
ne
s)
A)
B)  
C)  
$
*
$$ $ $
Pe
r1 Gi
lz
Sg
k
0.0
0.5
1.0
1.5
2.0
m
R
N
A 
ab
un
da
nc
e 
(re
la
tiv
e 
to
 h
ou
se
ke
ep
in
g 
ge
ne
s)
High Fat
High Fat + A-348441
High Fat + Dutasteride
High Fat + Dutasteride + A-348441
#p=0.07
Cy
p7
a1 Sh
p
0
1
2
3
m
R
N
A 
ab
un
da
nc
e 
(re
la
tiv
e 
to
 h
ou
se
ke
ep
in
g 
ge
ne
s)
Pe
r1 Gi
lz
Sg
k
0.0
0.5
1.0
1.5
2.0
m
R
N
A 
ab
un
da
nc
e 
(re
la
tiv
e 
to
 h
ou
se
ke
ep
in
g 
ge
ne
s)
High Fat
High Fat + A-348441
High Fat + Dutasteride
High Fat + Dutasteride + A-348441
$
$
#
Pe
r1 Gi
lz
Sg
k
0.0
0.5
1.0
1.5
2.0
m
R
N
A 
ab
un
da
nc
e 
(re
la
tiv
e 
to
 h
ou
se
ke
ep
in
g 
ge
ne
s)
High Fat
High Fat + A-348441
High Fat + Dutasteride
High Fat + Dutasteride + A-348441
*
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
o
lo
g
y
D
ow
nloaded from
 https://academ
ic.oup.com
/endo/advance-article-abstract/doi/10.1210/en.2019-00236/5518336 by Edinburgh U
niversity user on 23 August 2019
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
o
lo
g
y
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
o
lo
g
y
AD
VA
NC
E 
AR
TI
CL
E
AKT
β-tubulin
IRS2
IR
β-tubulin
IR IRS2
0.0
0.5
1.0
1.5
Re
la
tiv
e 
pr
ot
ei
n 
le
ve
l High fat
High fat + A-348441
A) Liver IR and IRS2
High fat High fat + A-348441
0.0
0.5
1.0
1.5
2.0
2.5
R
el
at
iv
e 
pr
ot
ei
n 
le
ve
l High fat
High fat + A-348441
High fat High fat + A-348441
0.0
0.5
1.0
1.5
R
el
at
iv
e 
pr
ot
ei
n 
le
ve
l
B) Liver AKT
C) Liver GSK-3β
High fat High fat + A-348441
High fat High fat + A-348441
GSK-3β
β-tubulin
High fat High fat + A-348441
D)
E)
β-tubulin
High fat
High fat + 
A-348441
Insulin -+ + + + +
pSer473 AKT 
AKT
β-tubulin 
pSer9 GSK-3b
GSK-3b
High fat
High fat + 
A-348441
Insulin -+ + + + +
High fat High fat + A-348441
0.0
0.1
0.2
0.3
Li
ve
r 
(p
G
SK
-3
β/
β-
Tu
bu
lin
)/(
G
SK
-3
β/
β-
Tu
bu
lin
)
High fat High fat + A-348441
0.0
0.1
0.2
0.3
0.4
LI
ve
r 
(p
AK
T/
β-
Tu
bu
lin
)/(
AK
T/
β-
Tu
bu
lin
)
Liver pSer473AKT
Liver pSer9GSK-3β
Control Knockout
0.0
0.5
1.0
1.5
2.0
Gl
uc
os
e A
UC
 ((
m
m
ol/
L*
m
in)
*1
03
)
High fat
High fat + A-348441
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
o
lo
g
y
D
ow
nloaded from
 https://academ
ic.oup.com
/endo/advance-article-abstract/doi/10.1210/en.2019-00236/5518336 by Edinburgh U
niversity user on 23 August 2019
